Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/109650
Title: Pyruvate kinase M2 and the mitochondrial ATPase Inhibitory Factor 1 provide novel biomarkers of dermatomyositis: a metabolic link to oncogenesis.
Author: Santacatterina, Fulvio
Sánchez Aragó, María
Catalán García, Marc
Garrabou Tornos, Glòria
Nuñez de Arenas, Cristina
Grau Junyent, Josep M. (Josep Maria)
Cardellach, Francesc
Cuezva, José M.
Keywords: Marcadors bioquímics
Dermatomiositis
Miositis
Malalties musculars
Biochemical markers
Dermatomyositis
Myositis
Muscular Diseases
Issue Date: 10-Feb-2017
Publisher: BioMed Central
Abstract: Background Metabolic alterations play a role in the development of inflammatory myopathies (IMs). Herein, we have investigated through a multiplex assay whether proteins of energy metabolism could provide biomarkers of IMs. Methods A cohort of thirty-two muscle biopsies and forty plasma samples comprising polymyositis (PM), dermatomyositis (DM) and sporadic inclusion body myositis (sIBM) and control donors was interrogated with monoclonal antibodies against proteins of energy metabolism using reverse phase protein microarrays (RPPA). Results When compared to controls the expression of the proteins is not significantly affected in the muscle of PM patients. However, the expression of β-actin is significantly increased in DM and sIBM in consistence with muscle and fiber regeneration. Concurrently, the expression of some proteins involved in glucose metabolism displayed a significant reduction in muscle of sIBM suggesting a repression of glycolytic metabolism in these patients. In contrasts to these findings, the expression of the glycolytic pyruvate kinase isoform M2 (PKM2) and of the mitochondrial ATPase Inhibitor Factor 1 (IF1) and Hsp60 were significantly augmented in DM when compared to other IMs in accordance with a metabolic shift prone to cancer development. PKM2 alone or in combination with other biomarkers allowed the discrimination of control and IMs with very high (>95%) sensitivity and specificity. Unfortunately, plasma levels of PKM2 were not significantly altered in DM patients to recommend its use as a non-invasive biomarker of the disease. Conclusions Expression of proteins of energy metabolism in muscle enabled discrimination of patients with IMs. RPPA identified the glycolysis promoting PKM2 and IF1 proteins as specific biomarkers of dermatomyositis, providing a biochemical link of this IM with oncogenesis.
Note: Reproducció del document publicat a: https://doi.org/10.1186/s12967-017-1136-5
It is part of: Journal of Translational Medicine, 2017, vol. 15, num. 29
Related resource: https://doi.org/10.1186/s12967-017-1136-5
URI: http://hdl.handle.net/2445/109650
ISSN: 1479-5876
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
668779.pdf3.43 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons